Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, explains how safety, resistance, and sequencing guide frontline therapy selection in CLL.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD
Advertisement
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, is a consultant hematologist and associate professor at Peter MacCallum Cancer Centre in Australia.
Articles by Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
4
Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’
5